De Vries P, Villalón C M, Saxena P R
Department of Pharmacology, and Cardiovascular Research Institute (COEUR), Erasmus University Medical Centre Rotterdam, The Netherlands.
Eur J Pharmacol. 1999 Jun 30;375(1-3):61-74. doi: 10.1016/s0014-2999(99)00197-1.
The last decade has witnessed a tremendous progress in the acute therapy of migraine, with sumatriptan, belonging to a new class of drugs, now known as 5-HT(1B/1D/1F) receptor agonists, leading the way. The undoubted success of sumatriptan stimulated the development of new triptans as well as other suitable pharmacological tools and experimental models to probe into complex migraine mechanisms. In this review, we discuss the main experimental models for migraine, against the background of the disease pathophysiology and 5-HT receptors considered most important for migraine therapy. We believe that the use of these migraine models will provide even better treatment for migraine patients in the next millennium.
过去十年见证了偏头痛急性治疗方面的巨大进展，舒马曲坦引领了这一进程，它属于一类新型药物，现被称为5-HT(1B/1D/1F)受体激动剂。舒马曲坦无疑取得的成功刺激了新型曲坦类药物以及其他合适的药理学工具和实验模型的开发，以探究复杂的偏头痛机制。在本综述中，我们在疾病病理生理学以及被认为对偏头痛治疗最为重要的5-HT受体的背景下，讨论偏头痛的主要实验模型。我们相信，这些偏头痛模型的应用将在新的千年为偏头痛患者提供更好的治疗。
